346 results on '"Davar, Diwakar"'
Search Results
52. Data from Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma
53. Supplementary Data from Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma
54. Supplementary Data from IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma
55. Supplementary figure legend 1 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
56. Supplementary Table from Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
57. Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients
58. Immunotherapy for Renal Cell Carcinoma
59. Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
60. Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable Melanoma
61. 588 Phase Ib study of the p38 inhibitor ARRY-614 with nivolumab, ipilimumab or nivolumab+ipilimumab in advanced solid tumors
62. 721 Pixatimod (P) in combination with nivolumab (N) +/- low-dose cyclophosphamide (Cy) in advanced cancers: a phase IIA basket trial
63. 1000 Melanoma lymph node metastases are associated with hypoxia and immunologic dysfunction
64. 716 AURELIO-04: a phase 2, open-label, single-arm, multicenter study to determine the efficacy and safety of SOT101 in combination with pembrolizumab in patients with selected advanced solid tumors
65. 1310 Dietary tryptophan catabolite released by intratumoralLactobacillus reuterifacilitates anti-PD-L1 therapy
66. 592 Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: part 1 results
67. 605 Neoadjuvant vidutolimod (vidu) and nivolumab (nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results
68. 763 Phase 1/2 dose escalation and dose expansion study of transCon TLR7/8 agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumor malignancies: initial results from dose escalation
69. 838 Combination MRx0518 and anti-PD-1 overcomes checkpoint inhibitor resistance via myeloid modulation
70. Immunotherapy of Cancer
71. Adjuvant Therapy
72. Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases
73. A retrospective analysis of the impact of the COVID-19 pandemic on staging at presentation of patients with invasive melanoma
74. Phase 2 Study of Intratumoral Vidutolimod With Intravenous Cemiplimab in Patients With Locally Advanced or Metastatic Merkel Cell Carcinoma (CMP-001- 009)
75. Predicting cancer immunotherapy response from gut microbiomes using machine learning models
76. Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy
77. Abstract CT218: First-in-human trial of intravenous MEDI9253, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors
78. Abstract CT119: A randomized, double-blind phase 2 evaluation of the anti-IL-8 monoclonal antibody BMS-986253 + nivolumab + ipilimumab vs nivolumab + ipilimumab in patients with advanced melanoma that progressed on/after anti-PD-(L)1 therapy
79. Abstract CT252: transcendIT-101: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors
80. Abstract CT041: Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)
81. Dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1).
82. Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers.
83. Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134).
84. Phase II study of nivolumab (nivo) with relatlimab (rela) in patients (pts) with first-line advanced melanoma: Early on-treatment major pathologic response on biopsy.
85. AMBER parts 1c and 1e: A phase 1 study of cobolimab plus dostarlimab in patients (pts) with advanced/metastatic melanoma.
86. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER).
87. A phase 1 multiple-ascending dose study to evaluate the safety and tolerability of XmAb23104 (PD-1 x ICOS) in subjects with selected advanced solid tumors (DUET-3).
88. A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in subjects with solid tumors.
89. The role of systemic therapy in melanoma brain metastases: a narrative review
90. Dietary tryptophan catabolite released by intratumoral Lactobacillus reuteri facilitates αPD-L1 therapy
91. Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
92. Malignant Melanoma in the Adolescent and Young Adult (AYA) Population
93. Toll-Like Receptor 9 Agonists in Cancer
94. Adjuvant Therapy of Melanoma
95. DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134.
96. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
97. 474 Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress)
98. 950 Final analysis: phase 1b study investigating intratumoral injection of toll-like receptor 9 agonist vidutolimod ± pembrolizumab in patients with PD-1 blockade–refractory melanoma
99. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
100. Thick melanoma is associated with low melanoma knowledge and low perceived health competence, but not delays in care
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.